S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACC...

por Silva-Pinto, A, Colombatti, R, Pasanisi, A, Arcioni, F, DeBonnett, L, Soliman, W, Sarkar, R, Cançado, R
Publicado 2022

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGE...

por Silva-Pinto, A. C., Colombatti, R., Pasanisi, A., Arcioni, F., DeBonnett, L., Soliman, W., Sarkar, R., Cançado, R. D.
Publicado 2022